Mylan N.V. (NASDAQ:MYL) had its price target raised by equities researchers at Royal Bank Of Canada from $32.00 to $37.00 in a research note issued to investors on Tuesday. The brokerage presently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price objective points to a potential downside of 1.04% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Cowen and Company restated a “market perform” rating and set a $36.00 price target (up previously from $30.00) on shares of Mylan N.V. in a research note on Thursday, October 5th. Mizuho restated a “buy” rating and set a $37.00 price target on shares of Mylan N.V. in a research note on Tuesday, October 24th. Zacks Investment Research upgraded Mylan N.V. from a “strong sell” rating to a “hold” rating and set a $43.00 price target on the stock in a research note on Tuesday, October 10th. Citigroup Inc. set a $42.00 price target on Mylan N.V. and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Finally, BidaskClub upgraded Mylan N.V. from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $41.49.

Mylan N.V. (NASDAQ MYL) opened at $37.39 on Tuesday. The company has a market cap of $19,155.95, a PE ratio of 7.17, a price-to-earnings-growth ratio of 1.93 and a beta of 1.38. The company has a quick ratio of 0.84, a current ratio of 1.35 and a debt-to-equity ratio of 1.20. Mylan N.V. has a fifty-two week low of $29.39 and a fifty-two week high of $45.87.

Mylan N.V. (NASDAQ:MYL) last announced its earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the Zacks’ consensus estimate of $1.20 by ($0.10). The firm had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $3.09 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.38 earnings per share. equities analysts predict that Mylan N.V. will post 4.63 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Mylan N.V. (MYL) Price Target Raised to $37.00 at Royal Bank Of Canada” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.watchlistnews.com/mylan-n-v-myl-price-target-raised-to-37-00-at-royal-bank-of-canada/1684888.html.

Several hedge funds have recently made changes to their positions in MYL. Bank of Nova Scotia raised its stake in shares of Mylan N.V. by 1.9% during the 1st quarter. Bank of Nova Scotia now owns 10,525 shares of the company’s stock worth $410,000 after buying an additional 196 shares during the period. Factory Mutual Insurance Co. raised its stake in shares of Mylan N.V. by 250.0% during the 2nd quarter. Factory Mutual Insurance Co. now owns 161,000 shares of the company’s stock worth $6,250,000 after buying an additional 115,000 shares during the period. Waverton Investment Management Ltd acquired a new position in Mylan N.V. in the 2nd quarter valued at $396,000. Smith Shellnut Wilson LLC ADV raised its stake in Mylan N.V. by 12.1% in the 2nd quarter. Smith Shellnut Wilson LLC ADV now owns 18,807 shares of the company’s stock valued at $813,000 after purchasing an additional 2,025 shares during the last quarter. Finally, Bank of Montreal Can raised its stake in Mylan N.V. by 1.2% in the 2nd quarter. Bank of Montreal Can now owns 1,063,225 shares of the company’s stock valued at $41,276,000 after purchasing an additional 12,347 shares during the last quarter. 72.01% of the stock is owned by institutional investors and hedge funds.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan N.V. (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.